United Health Products, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
OQB
United Health Products reports continued operating losses and significant regulatory hurdles as it seeks FDA approval for its CelluSTAT hemostatic gauze.
OQB
United Health Products' 2024 10-K filing reveals ongoing efforts to secure FDA approval for its CelluSTAT hemostatic gauze while navigating financial challenges and operational adjustments.
OQB
United Health Products reports its 2023 financial results and provides an update on its FDA application for its hemostatic gauze product.